Hypothesis

Protective intracellular aggregates are not static garbage dumps but dynamic, chaperone‑enriched condensates that undergo a regulated maturation step from reversible liquid‑like assemblies to irreversibly cross‑β amyloid‑like structures. When proteostasis capacity is intact, the system stalls aggregation at the liquid‑like stage, sequestering damaged proteins while preserving solubility and function. Age‑related decline in specific chaperones or post‑translational modifying enzymes accelerates the transition to toxic fibrils, converting a beneficial sequestration mechanism into a pathogenic process. Therapeutic strategies that preserve the reversible, liquid‑like state—or that block the maturation step—should extend healthspan by maintaining the protective sequestration function without indiscriminately clearing aggregates that may be essential.

Mechanistic Basis

• Liquid‑liquid phase separation (LLPS) driven by low‑complexity domains and chaperone binding creates reversible condensates that sequester misfolded proteins (see protective aggregates in long‑lived nematodes)[1].
• Maturation trigger: accumulation of specific modifications (e.g., phosphorylation of tau, acetylation of p53) or depletion of HSP‑70/HSP‑90 shifts the equilibrium toward β‑sheet-rich fibrils, a step observed in Alzheimer’s‑associated p53‑tau oligomers[4].
• Size‑dependent fitness effect: In E. coli, polar aggregates of optimal size protect daughter cells, whereas larger aggregates impair division, suggesting a size threshold for the liquid‑to‑solid transition[3].

Testable Predictions

1. Chaperone modulation: Overexpressing HSP‑70 or a co‑chaperone that preferentially binds early LLPS intermediates will increase the proportion of liquid‑like aggregates, extend lifespan in C. elegans, and reduce fibrillar tau accumulation in AD model mice.
2. Modification blockade: Inhibiting the kinase responsible for tau phosphorylation (e.g., GSK‑3β) or the acetyltransferase acting on p53 will stall aggregation at the liquid‑like state, preserving proteasome activity and decreasing neurodegeneration despite ongoing stress.
3. Size‑sensing clearance: Enhancing autophagy machinery that selectively removes aggregates above a critical size (while sparing sub‑threshold condensates) will improve healthspan without compromising the protective sequestration function.
4. Biomarker shift: In healthy elderly brains, soluble fractions will show enrichment of chaperone‑bound, liquid‑like aggregate markers (e.g., FRAP‑recoverable GFP‑tagged proteins), whereas AD brains will show loss of this signal and gain of insoluble, thioflavin‑S‑positive fibrils.

Experimental Approach

• Use C. elegans strains expressing a fluorescently tagged aggregation‑prone protein (e.g., polyQ‑YFP) alongside HSP‑70 overexpression or CRISPR‑knock‑in of a phospho‑deficient tau homolog. Measure lifespan, motility, and aggregate dynamics via time‑lapse confocal microscopy and FRAP.
• In murine AD models, administer selective GSK‑3β inhibitors or p53 acetyltransferase inhibitors, then assess soluble vs. insoluble tau/p53 levels (Western blot, filter trap), cognitive performance, and histologic aggregate composition (Thioflavin S, immunofluorescence for chaperones).
• Apply size‑selective autophagy enhancers (e.g., spermidine) and quantify aggregate size distribution by super‑resolution imaging, correlating with markers of proteasome activity and cellular senescence.

Implications

If validated, this hypothesis reframes anti‑aggregation therapeutics: rather than dissolving all aggregates, we aim to lock the proteostasis network in a protective, reversible phase‑separated state. Such an approach could preserve the beneficial sequestration of damaged proteins while preventing the emergence of cytotoxic amyloids, offering a nuanced path to extend healthspan without compromising the cell’s intrinsic damage‑containment strategy.